Evolent Health, Inc. (EVH) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EVH Revenue Growth
Revenue Breakdown (FY 2025)
EVH's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
EVH Revenue Analysis (2014–2025)
As of May 8, 2026, Evolent Health, Inc. (EVH) generated trailing twelve-month (TTM) revenue of $1.89 billion, reflecting modest growth of +2.6% year-over-year. The most recent quarter (Q1 2026) recorded $496.2 million in revenue, up 5.9% sequentially.
Looking at the longer-term picture, EVH's 5-year compound annual growth rate (CAGR) stands at +15.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $2.55 billion in 2024.
Revenue diversification analysis shows EVH's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PINC (-16.2% YoY), ALHC (+41.8% YoY), and HQY (+9.5% YoY), EVH has underperformed the peer group in terms of revenue growth. Compare EVH vs PINC →
EVH Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EVHCurrent | $1.9B | +2.6% | +15.2% | -0.2% | |
 PINC | $1.0B | -16.2% | -4.9% | 0.1% | |
 ALHC | $3.9B | +41.8% | +32.7% | 0.4% | |
 HQY | $1.3B | +9.5% | +12.4% | 24.6% | |
 TDOC | $2.5B | -1.5% | +18.3% | -10.4% | |
 OSCR | $11.7B | +31.9% | +81.8% | -3.4% |
EVH Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.88B | -26.6% | $283.0M | 15.1% | $-4,434,000 | -0.2% |
| 2024 | $2.55B | +30.1% | $367.4M | 14.4% | $-40,485,000 | -1.6% |
| 2023 | $1.96B | +45.3% | $460.5M | 23.4% | $-71,211,000 | -3.6% |
| 2022 | $1.35B | +48.9% | $316.6M | 23.4% | $3.6M | 0.3% |
| 2021 | $908.0M | -1.8% | $250.4M | 27.6% | $-42,411,000 | -4.7% |
| 2020 | $924.6M | +34.6% | $228.1M | 24.7% | $-262,847,000 | -28.4% |
| 2019 | $687.1M | +9.6% | $174.1M | 25.3% | $-308,885,000 | -45.0% |
| 2018 | $627.1M | +44.2% | $299.2M | 47.7% | $-47,480,000 | -7.6% |
| 2017 | $434.9M | +71.1% | $165.6M | 38.1% | $-72,840,000 | -16.7% |
| 2016 | $254.2M | +162.4% | $99.0M | 39.0% | $-237,419,000 | -93.4% |
See EVH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEVH — Frequently Asked Questions
Quick answers to the most common questions about buying EVH stock.
Is EVH's revenue growth accelerating or slowing?
EVH revenue growth slowed to +2.6%, below the 5-year CAGR of +15.2%. TTM revenue is $1.9B. The deceleration marks a shift from historical growth rates.
What is EVH's long-term revenue growth rate?
Evolent Health, Inc.'s 5-year revenue CAGR of +15.2% reflects the variable expansion pattern. Current YoY growth of +2.6% is near this long-term average.
How is EVH's revenue distributed by segment?
EVH reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.